InMed Pharmaceuticals Q3 2026 Earnings Report

InMed Pharmaceuticals EPS Results

• Actual EPS: -$0.69
• Consensus EPS: -$94.44
• Beat/Miss: Beat by +$93.75
• One Year Ago EPS: N/A

InMed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.20 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

InMed Pharmaceuticals Announcement Details

• Quarter: Q3 2026
• Date: 5/6/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 6, 2026
• Conference Call Time: 7:00AM ET

InMed Pharmaceuticals (NASDAQ:INM) is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.

The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders. Among these, INM-755 is being developed for rare blistering skin disorders and other dermal conditions, while INM-088 is focused on neuroprotective applications such as glaucoma and glioblastoma. InMed’s approach emphasizes the selection of specific cannabinoid compounds based on their pharmacological profiles and the engineering of drug delivery systems that enhance stability, bioavailability and patient compliance.

To support its research and clinical objectives, InMed owns BayMedica, a wholly owned subsidiary specializing in the production of high-purity cannabinoid materials under current Good Manufacturing Practices (cGMP). Operating out of a facility in California, BayMedica supplies both internal pipeline programs and external pharmaceutical partners with consistent, analytically characterized cannabinoids. This vertically integrated capability helps mitigate supply chain risks and ensures that InMed can maintain control over critical stages of its development process.

Since its founding, InMed has assembled a management team with deep expertise in biotechnology, pharmaceuticals and cannabinoid science. Led by President and Chief Executive Officer Robert C. Loop Jr., the company continues to expand its intellectual property portfolio while advancing multiple candidates toward clinical milestones. InMed serves patients and research collaborators across North America and is actively exploring strategic partnerships to accelerate the delivery of its cannabinoid-based therapies to global markets.